The Combination of the PARP Inhibitor Olaparib and the ATR Inhibitor VE-821 Selectively Targets ATM-Deficient Lung Cancer Cells

被引：0
|
作者：
Jette, N. [1 ]
Radhamani, S. [1 ]
Arthur, G. [1 ]
Ye, R. [1 ]
Goutam, S. [1 ]
Boylos, A. [1 ]
Petersen, L. [1 ]
Bose, P. [1 ]
Bebb, G. [1 ]
Lees-Miller, S. [1 ]
机构：
[1] Univ Calgary, Calgary, AB, Canada
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
Olaparib; VE-821; ATM;
D O I：
10.1016/j.jtho.2019.08.1192
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.14-41
引用
收藏
页码：S570 / S571
页数：2
相关论文
共 50 条
  • [21] Inhibition of ATR kinase with the selective inhibitor VE-821 results in radiosensitization of cells of promyelocytic leukaemia (HL-60)
    Vavrova, Jirina
    Zarybnicka, Lenka
    Lukasova, Emilie
    Rezacova, Martina
    Novotna, Eva
    Sinkorova, Zuzana
    Tichy, Ales
    Pejchal, Jaroslav
    Durisova, Kamila
    RADIATION AND ENVIRONMENTAL BIOPHYSICS, 2013, 52 (04) : 471 - 479
  • [22] Inhibition of ATR kinase with the selective inhibitor VE-821 results in radiosensitization of cells of promyelocytic leukaemia (HL-60)
    Jiřina Vávrová
    Lenka Zárybnická
    Emilie Lukášová
    Martina Řezáčová
    Eva Novotná
    Zuzana Šinkorová
    Aleš Tichý
    Jaroslav Pejchal
    Kamila Ďurišová
    Radiation and Environmental Biophysics, 2013, 52 : 471 - 479
  • [23] 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells
    Ruoxi Hong
    Fei Ma
    Weimin Zhang
    Xiying Yu
    Qing Li
    Yang Luo
    Changjun Zhu
    Wei Jiang
    Binghe Xu
    BMC Cancer, 16
  • [24] 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells
    Hong, Ruoxi
    Ma, Fei
    Zhang, Weimin
    Yu, Xiying
    Li, Qing
    Luo, Yang
    Zhu, Changjun
    Jiang, Wei
    Xu, Binghe
    BMC CANCER, 2016, 16
  • [25] ATM-DEFICIENT GASTRIC CANCER CELLS ARE SENSITIVE TO THE POLY (ADP-RIBOSE) POLYMERASE-1 INHIBITOR, OLAPARIB
    Kubota, E.
    Lees-Miller, S. P.
    Bebb, D. G.
    ANNALS OF ONCOLOGY, 2012, 23 : 37 - 37
  • [26] Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells
    Rebecca L. Lloyd
    Paul W. G. Wijnhoven
    Antonio Ramos-Montoya
    Zena Wilson
    Giuditta Illuzzi
    Katarzyna Falenta
    Gemma N. Jones
    Neil James
    Christophe D. Chabbert
    Jonathan Stott
    Emma Dean
    Alan Lau
    Lucy A. Young
    Oncogene, 2020, 39 : 4869 - 4883
  • [27] Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells
    Lloyd, Rebecca L.
    Wijnhoven, Paul W. G.
    Ramos-Montoya, Antonio
    Wilson, Zena
    Illuzzi, Giuditta
    Falenta, Katarzyna
    Jones, Gemma N.
    James, Neil
    Chabbert, Christophe D.
    Stott, Jonathan
    Dean, Emma
    Lau, Alan
    Young, Lucy A.
    ONCOGENE, 2020, 39 (25) : 4869 - 4883
  • [28] Erratum to: 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells
    Ruoxi Hong
    Fei Ma
    Weimin Zhang
    Xiying Yu
    Qing Li
    Yang Luo
    Changjun Zhu
    Binghe Xu
    Wei Jiang
    BMC Cancer, 16
  • [29] Case Report: Combination of Olaparib With Chemotherapy in a Patient With ATM-Deficient Colorectal Cancer
    Papageorgiou, Georgios I.
    Fergadis, Evangelos
    Skouteris, Nikos
    Christakos, Evridiki
    Tsakatikas, Sergios A.
    Lianos, Evangelos
    Kosmas, Christos
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [30] ZEB1 inhibition sensitizes cells to the ATR inhibitor VE-821 by abrogating epithelial-mesenchymal transition and enhancing DNA damage
    Song, Na
    Jing, Wei
    Li, Ce
    Bai, Ming
    Cheng, Yu
    Li, Heming
    Hou, Kezuo
    Li, Yanrong
    Wang, Kai
    Li, Zhi
    Liu, Yunpeng
    Qu, Xiujuan
    Che, Xiaofang
    CELL CYCLE, 2018, 17 (05) : 595 - 604
12345